Cough induced by losartan with resolution after substitution with enalapril

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 548-551

  Dashti Khavidaki, Simin ^a   Faghihi, Toktam ^a   Ahmadi, Farrokhlegha ^b   Khalili, Hossein ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

angiotensin converting enzyme inhibitor; angiotensin receptor blockers; cough; enalapril; losartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; PROSTAGLANDIN; SIMVASTATIN; SUBSTANCE P;

ADULT; ARTICLE; CASE REPORT; COUGHING; DRUG SUBSTITUTION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IRAN; MALE; PROTEINURIA;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COUGH; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; LOSARTAN;

EID: 41649102616     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.003     Document Type: Article

References (11)

1. Nussberger J., and Koike H. Antagonizing the angiotensin II subtype I receptor: A focus on olmesartan medoxomil. Clin Ther 26 (2004) A12-A20
2. Dicpinigaitis P. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guide-lines. Chest 129 (2006) 169S-173S
3. Pylypchuk G. ACE inhibitor versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 32 (1998) 1060-1066
4. Paster R., Snavely D., Sweet A., et al. Use of losartan in the treatment of hypertensive patients with a history of cough induced by angiotensin-converting enzyme inhibi-tors. Clin Ther 20 (1998) 978-989
5. Sadeghi N., and Panje W. Angiotensin-converting enzyme in-hibitor therapy: Adverse effects encountered by otolaryngologist. Curr Opin Otolaryngol Head Neck Surg. 9 (2001) 162-165
6. Coca A., Calvo C., García-Puig J., et al., MAPAVELInvestigators. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan andenalapril in adults with mild to moderate essential hyptension, as assessed by ambulatory blood pressure moni-toring: The MAPAVEL Study (Monitorizacíon Ambulatoria Presión Arterial APROVEL). Clin Ther 24 (2002) 126-138
7. Lacourcière Y., Brunner H., Irwin R., et al., Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 12 (1994) 1387-1393
8. Goldberg A., Dunlay M., and Sweet C. Safety and tolerabili-ty of losartan potassium, an angiotensin II receptor an-tagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 75 (1995) 793-795
9. Ramsay L., Yeo W., and Losar-tan Cough Study Group. ACE in-hibitors, angiotensin II antagonistsand cough. J Hum Hypertens 9 Suppl 5 (1995) S51-S54
10. K-DOQI guidelines (2007). http://www.kidney.org/professionals/kdoqi/guidelines
11. Naranjo C., Busto O., Sellers E., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 (1981) 239-245